FDA Reorganization Of New Drug Office Would Split Neuropharmaceutical Division

Neurology and psychiatry drugs would be reviewed in separate divisions under the proposed restructuring. The reorganization, which aims to group products by therapeutic indications and integrate the review of biologics and drugs, would eliminate ODE V.